Aysegul Sakin1, Suleyman Sahin2, Abdullah Sakin3, Mehmet Naci Aldemir3, Irfan Bayram4, Cetin Kotan5. 1. Department of Internal medicine, University of Health Sciences, Van Research and Training Hospital, Van, Turkey. 2. Department of Medical Oncology, University of Health Sciences, Van Research and Training Hospital, Van, Turkey. 3. Department of Medical Oncology, Yuzuncu Yil University Medical School, 65030, Van, Turkey. 4. Department of Pathology, Yuzuncu Yil University Medical School, 65030, Van, Turkey. 5. Department of General surgery, Yuzuncu Yil University Medical School, 65030, Van, Turkey.
Abstract
INTRODUCTION: The effect of obesity on response to neoadjuvant chemotherapy (NACT) remains unknown. We aimed to investigate the effect of obesity on response to NACT and survival in locally-advanced gastric cancer (GC). METHODS: From 2010 to 2019, 142 GC patients with clinical stage III disease who underwent curative surgery after NACT were enrolled. Patients were divided into 3 groups according to body mass index (BMI) as follows; BMI < 25 kg/m2, BMI = 25-30 kg/m2, and BMI > 30 kg/m2. The Mandard tumor regression grading system was used for tumor regression grade (TRG). RESULTS: Of the 142 GC patients, 45(31.7%) were female. The median age was 58 years. BMI was < 25 kg/m2 in 60 (42.3%) patients, 25-30 kg/m2 in 44 (31%) patients, and > 30kg/m2 in 38 (26.8%) patients. The numbers of patients with TRGI-II, TRGIII, and TRGIV-V were 35 (24.6%), 44 (31%), and 63 (44.4%), respectively. There was no statistically significant difference among BMI groups in terms of disease-free survival (DFS) and overall survival (OS) (p = 0.919 and p = 0.398, respectively). According to TRG groups; mDFS was 46 months in TRG I-II, 28 months in TRG III, and 18 months in TRG IV-V (p <0.001). In multivariate analysis, presence of perineural invasion and lymphovascular invasion were the factors affecting TRG. CONCLUSION: In our study, we found that pre-treatment obesity did not affect the TRG in clinical stage III GC patients. However, a better TRG status was associated with improved survival.<br />.
INTRODUCTION: The effect of obesity on response to neoadjuvant chemotherapy (NACT) remains unknown. We aimed to investigate the effect of obesity on response to NACT and survival in locally-advanced gastric cancer (GC). METHODS: From 2010 to 2019, 142 GC patients with clinical stage III disease who underwent curative surgery after NACT were enrolled. Patients were divided into 3 groups according to body mass index (BMI) as follows; BMI < 25 kg/m2, BMI = 25-30 kg/m2, and BMI > 30 kg/m2. The Mandard tumor regression grading system was used for tumor regression grade (TRG). RESULTS: Of the 142 GC patients, 45(31.7%) were female. The median age was 58 years. BMI was < 25 kg/m2 in 60 (42.3%) patients, 25-30 kg/m2 in 44 (31%) patients, and > 30kg/m2 in 38 (26.8%) patients. The numbers of patients with TRGI-II, TRGIII, and TRGIV-V were 35 (24.6%), 44 (31%), and 63 (44.4%), respectively. There was no statistically significant difference among BMI groups in terms of disease-free survival (DFS) and overall survival (OS) (p = 0.919 and p = 0.398, respectively). According to TRG groups; mDFS was 46 months in TRG I-II, 28 months in TRG III, and 18 months in TRG IV-V (p <0.001). In multivariate analysis, presence of perineural invasion and lymphovascular invasion were the factors affecting TRG. CONCLUSION: In our study, we found that pre-treatment obesity did not affect the TRG in clinical stage III GC patients. However, a better TRG status was associated with improved survival.<br />.
Entities:
Keywords:
Body mass index; Gastric cancer; Obesity; tumor regression grade
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: Kai A Bickenbach; Brian Denton; Mithat Gonen; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2012-09-14 Impact factor: 5.344
Authors: Alex Farr; Myriam Stolz; Lukas Baumann; Zsuzsanna Bago-Horvath; Elisabeth Oppolzer; Georg Pfeiler; Michael Seifert; Christian F Singer Journal: Breast Date: 2017-04-07 Impact factor: 4.380
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396